A	B	C
1	Main
2		Brand	Onpattro
3		Generic	patisiran
4		Indication	ATTR Amyloidosis. Neuropathy & Cardiomyopathy.
5		Clinical Trials
6			Phase III "APOLLO-B" n=360 ATTR with cardiomyopathy
7			6MW PE met at 12 months: +14.7m, p=0.0162
8			'-8.15 for patisiran, -21.345 for placebo
9			Initially presented at ISA, press release 8/2022; HFSA 10/2022
10			0.3mg/kg IV q3w
11			MACE HR=0.839 p=NS